LIVZON GROUP(SZ:000513)2023-02-23 08:12Group 1: Financial Performance - The company achieved a compound annual growth rate (CAGR) of approximately 17% in net profit over the past decade (2012-2021), demonstrating strong sustainable growth capabilities [1] - The dividend yield has remained between 2.3% and 3.8% over the past five years (excluding 2022), with cumulative dividends exceeding 6 billion yuan over the past ten years (excluding 2022) [2][10] - The company was included in the "Abundant Return List" and "Sincere Report List" for cash dividends by the China Securities Association in June 2022 [10] Group 2: Innovation and R&D - The company has increased its investment in innovative R&D, focusing on high-barrier complex formulation development, with leading long-acting controlled-release technologies [1] - The company has a robust pipeline of products in the fields of chemical drugs, biological drugs, traditional Chinese medicine, raw materials, and reagents, maintaining competitive advantages across various business segments [1] - The company’s biosimilar drug, Tocilizumab, has been approved for marketing, and the company is actively developing other complex formulations [6] Group 3: Market Expansion and Product Development - The company is expanding its product line in assisted reproduction, with revenues in this sector reaching 2.092 billion yuan, accounting for 22.3% of total revenue in the first three quarters of 2022 [3] - The company has a comprehensive product line in assisted reproduction, including ovulation induction drugs, which have the highest market share [3] - The company is actively pursuing international collaborations and licensing agreements to enhance its R&D and sales pipeline [2] Group 4: ESG and Shareholder Returns - The company has been committed to ESG principles, with a continuous improvement in sustainable development capabilities [2] - The company has published ESG reports for six consecutive years, and its MSCI ESG rating was upgraded to AA in July 2022 [2] - The company is implementing various measures, including share buybacks, to share growth dividends with investors [2] Group 5: Product Pipeline and Clinical Trials - The company’s biosimilar drug, Semaglutide, is in Phase III clinical trials for Type 2 diabetes, with over 30 clinical trial centers initiated [5] - The company’s recombinant COVID-19 vaccine has been included in emergency use for sequential booster immunization since September 2022 [6] - The company is advancing its research on various formulations, including microsphere platforms, which have high industrialization barriers [7]